Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot PET Imaging Study of [89Zr]DFO-YS5 in Multiple Myeloma
NCT05892393Phase 1Recruiting
- Start
- Jun 2023
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of FG-3180 in multiple myeloma (MM) (2 cohorts). Primary endpoints: Sensitivity of metastatic lesion detection at 1 week, Median maximum standardized uptake value at 1 week and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
FG-3180
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05892393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892393.